Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
T Cell-Depleted Hematopoietic Stem Cell Transplantation-University of Nebraska-Multiple Myeloma
- Development stage
- Unknown
- Lead developer
- University of Nebraska Medical Center
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
T Cell-Depleted Hematopoietic Stem Cell Transplantation-University of Nebraska-Multiple Myeloma refers to a specific autologous cell therapy protocol investigated at the University of Nebraska for the treatment of multiple myeloma. The procedure involves the ex vivo processing of a patient's harvested peripheral blood stem cells to enrich for CD34+ hematopoietic progenitor cells while depleting T lymphocytes, typically through immunomagnetic selection. This T cell-depleted graft is administered intravenously to patients following high-dose conditioning chemotherapy (such as melphalan) to restore hematopoiesis. In the context of University of Nebraska clinical trials, this approach is specifically used to study the kinetics of immune system recovery and the effectiveness of post-transplant vaccinations, such as the tetanus toxoid vaccine, compared to standard unmanipulated autologous stem cell transplantation.
- Other names
- T cell-depleted autologous hematopoietic stem cell transplantationCD34+ selected autologous HSCTautologous CD34 HSCTT Cell-Depleted Hematopoietic Stem Cell Transplantation
Beyond the preview
Go deeper on T Cell-Depleted Hematopoietic Stem Cell Transplantation-University of Nebraska-Multiple Myeloma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on T Cell-Depleted Hematopoietic Stem Cell Transplantation-University of Nebraska-Multiple Myeloma.